Incidence of PI3K pathway aberrations and their impact on response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) subtypes

被引：0
|
作者：
Basho, Reva K.
Trevarton, Alex
Hess, Kenneth R.
Fu, Chunxiao
Lau, Rosanna
Lin, Chih-Hsu
Lichtarge, Olivier
Yang, Wei Tse
Symmans, William Fraser
Moulder, Stacy L.
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Baylor Coll Med, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.588
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
588
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Transcriptomic modification induced by the first cycle of neoadjuvant chemotherapy impacts response to treatment in triple-negative breast cancer (TNBC)
    Desmoulins, I.
    Chardin, D.
    Richard, C.
    Arnould, L.
    Boidot, R.
    Humbert, O.
    ANNALS OF ONCOLOGY, 2021, 32 : S494 - S494
  • [32] Preliminary results of a prospective pilot study of cisplatin (C) and doxorubicin (D) as neoadjuvant chemotherapy (NACT) for locally advanced triple-negative breast cancer (TNBC)
    Zhukova, Lyudmila
    Okruzhnova, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] The role of stromal tumor infiltrating lymphocytes (sTILs) as a predictive biomarker for carboplatin-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC).
    Walsh, Elaine M.
    O'Loughlin, Mark
    Shalaby, Aliaa
    Webber, Mark
    Kerin, Michael J.
    Glynn, Sharon A.
    Callagy, Grace
    Keane, Maccon M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Impact of microRNA variants on PI3K/AKT signaling in triple-negative breast cancer: comprehensive review
    Mehrtabar, Ehsan
    Khalaji, Amirreza
    Pandeh, Mojtaba
    Farhoudian, Aram
    Shafiee, Nadia
    Shafiee, Atefe
    Ojaghlou, Fatemeh
    Mahdavi, Parinaz
    Soleymani-Goloujeh, Mehdi
    MEDICAL ONCOLOGY, 2024, 41 (09)
  • [35] Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
    Jung, Yoon Yang
    Hyun, Chang Lim
    Jin, Min-Sun
    Park, In Ae
    Chung, Yul Ri
    Shim, Bobae
    Lee, Kyu Ho
    Ryu, Han Suk
    JOURNAL OF BREAST CANCER, 2016, 19 (03) : 261 - 267
  • [36] The response to neoadjuvant chemotherapy and prognosis of triple-negative breast cancer patients.
    Nakano, E.
    Hojo, T.
    Masumura, K.
    Kikuyama, M.
    Akashi, S.
    Kinoshita, T.
    CANCER RESEARCH, 2009, 69 (02) : 337S - 337S
  • [37] PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer
    Zhang, Huan-ping
    Jiang, Rui-yuan
    Zhu, Jia-yu
    Sun, Ke-na
    Huang, Yuan
    Zhou, Huan-huan
    Zheng, Ya-bing
    Wang, Xiao-jia
    BREAST CANCER, 2024, 31 (04) : 539 - 551
  • [38] Role of piperine in chemoresistance of triple-negative breast cancer: Potential modulation of PI3K/Akt/mTOR pathway
    Fattah, Aliaa Abdel
    Zaki, Amr
    Kamel, Kohinour
    Yasser, Lidia
    Barsom, Marina
    Ahmed, MennatAllah
    Gamal, Mohamed
    Hakeem, Andrew
    El-Kersh, Dina
    Attia, Yasmeen
    BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (11) : 2539 - 2540
  • [39] Trends, patterns, and outcomes of neoadjuvant chemotherapy (NACT) use among patients with early invasive triple negative breast cancer (TNBC)
    Jackson, Inimfon
    Lei, Xiudong
    Malinowski, Catalina
    Giordano, Sharon H.
    Chavez-MacGregor, Mariana
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Characteristics of residual tumor after neoadjuvant chemotherapy (nact) may predict outcomes in patients with triple negative breast cancer (tnbc)
    Frolova, M.
    Glazkova, E.
    Petrovsky, A.
    Rumyantsev, A.
    Stenina, M.
    Tjulandin, S.
    BREAST, 2023, 68 : S58 - S58
12345